Topic - Christopher Viehbacher

Viehbacher said on Tuesday, after the company reported better-than-expected second quarter results, that Biogen is “laser focused” on changing the company’s share price trajectory.

Biogen to bulk up rare disease treatments with $7 billion Reata acquisition →

3 years in, Sanofi CEO has transformed drugmaker →